Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rude Awakening Could Await China (China)

This article was originally published in PharmAsia News

Executive Summary

China's lack of oversight concerning its pharmaceutical and food industries may lead to a global backlash against China as countries shy away from or even ban importation of Chinese medicines and food products. The United States on May 24 requested that China increase its oversight on food and drug export products. America and China currently are engaged in wide-ranging trade talks in which the United States is focusing on demanding China's currency be permitted to fluctuate more. The U.S. Food and Drug administration already has banned all U.S. imports of China-made toothpaste, after some Chinese toothpaste was found to contain an ingredient used in automotive antifreeze. Further problems in sensitive industries such as pharmaceuticals and food products may lead to trade embargo legislation against China from the U.S. Congress. Such incidents also would reverberate around the world, wounding China's food and pharmaceutical export companies. (Click here for more - May Require Free Registration

You may also be interested in...

Teligent Moves To Consolidate Shares To Stay Listed

Teligent has followed through with plans to condense its outstanding shares to raise their value and maintain a stock-exchange listing. Meanwhile, the company revealed a sizeable loss for the first quarter of this year, as it gave the latest on its warning letter-stricken facility in Buena, New Jersey.

WHO Prequalifies Celltrion’s Rituximab

Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.

Medac Will Market Fresenius Kabi’s Adalimumab In Germany

Fresenius Kabi’s Idacio biosimilar adalimumab rival to Humira will from the start of June be marketed in Germany by Medac, following a deal between the two companies.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts